Morphological damage to cardiomyocytes or loss of viability (structural cardiotoxicity) is a common cause of attrition in preclinical and clinical drug development. Currently, no predictive in vitro approaches are available to detect this liability early in drug discovery, and knowledge of the mechanisms involved is limited. Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) and the rat myoblastic H9c2 cell lines were used to phenotypically profile a panel of structural cardiotoxins by livecell fluorescent imaging of mitochondrial membrane potential, endoplasmic reticulum integrity, Ca 2+ mobilization, and membrane permeability combined with an assessment of cell viability (ATP depletion). Assay results were normalized to known therapeutically relevant concentrations. By comparing the outcome of each assay to the known in vivo effects, hESC-CMs offered an improved model over H9c2 cells for the detection of structural cardiotoxicity at therapeutically relevant concentrations. Inhibition of the spontaneously beating phenotype, a feature of stem cell-derived cardiomyocytes, revealed some degree of cardioprotection following 10 out of 13 structural cardiotoxins, illustrating the intricate relationship between the function and structure of cardiomyocytes. Classification of structural cardiotoxins into mechanistic themes revealed mitochondria and calcium mobilization to be major distal targets, with only 4 out of 15 compounds affecting contractile function in freshly isolated canine cardiomyocytes at therapeutically relevant concentrations. Our data demonstrate the utility of hESC-CMs during drug development to support structural cardiotoxicity hazard identification and to gain insight into the intricate mechanisms implicated in structural cardiotoxicity.
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Cardiotoxicity, a major cause of attrition in preclinical and clinical drug development, has been widely associated with both small and large molecules (Abassi et al., 2012; Albini et al., 2010; Laverty et al., 2011) . Additionally, it may emerge preclinically in animals or during clinical testing and postmarketing either acutely, chronically, or several years after the cessation of treatment (Gwathmey et al., 2009; Mellor et al., 2011) . It is often a dose-limiting toxicity and the cause of severe morbidity (Schimmel et al., 2004) .
Drug-induced cardiovascular toxicity affects all components and functions of the cardiovascular system, and it can be functional (acute alteration of the mechanical function of the myocardium) or structural in nature (morphological damage to cardiomyocytes or loss of viability) as previously defined by Laverty et al. (2011) . The interaction and sequence in which both functional and structural cardiotoxicity manifest is compound specific (e.g., one compound may cause structural cardiotoxicity and the function of the cardiovascular system is only compromised many months after the developed of the structural effect) (Murphy and Dargie, 2007) . Evaluation of the potential for either functional or structural cardiotoxicity by novel compounds is essential for the discovery of safe drugs. Currently, in vitro screening strategies are predominately focused on identifying functional cardiotoxicity through the detection of ECG abnormalities via drug-induced QT interval prolongation by ion channel screening and measurement of cardiac action potentials, and changes in ECHO through cardiomyocyte contractility abnormalities (Harmer et al., 2012; Pollard et al., 2010) . However, cardiovascular toxicity can also occur due to morphological damage to cardiomyocytes or loss of cardiomyocyte viability (structural cardiotoxicity), resulting in cardiomyopathy and heart failure (Abassi et al., 2012; Force and Kolaja, 2011) . Currently, in vitro screening strategies and insight into the mechanisms of toxicity are lacking in this area requiring further development and prioritization. The relationship between changes in left ventricular ejection fraction (LVEF) due to changes in contractility (functional cardiotoxicity) or morphological damage (structural cardiotoxicity) is currently unclear, with the relative importance of each to be determined.
The molecular and cellular mechanisms of structural cardiotoxicity vary from compound to compound, and the contribution of each mechanism to the overall toxicity induced by a compound remains to be fully elucidated (Berthiaume and Wallace, 2007; Force et al., 2007; Gao et al., 2008; Kerkela et al., 2006 Kerkela et al., , 2009 Minamino and Kitakaze, 2010; TokarskaSchlattner et al., 2002; Wallace, 2007) . Owing to its incidence during late-stage discovery (Laverty et al., 2011) , drug-induced structural cardiotoxicity has been, and remains a significant hurdle to the development of safe and effective medicines. Therefore, the development of predictive cellular in vitro models that can be applied to the development of novel compounds and identification of mechanisms of toxicity during early phases of drug discovery would undoubtedly help to reduce the hazard and to provide insight into this toxicity.
Until recently, cardiac in vitro models consisted of cell lines, rat myoblastic H9c2 cells, which pose a predominant skeletal muscle phenotype and are unresponsive to electrical stimulation (Kimes and Brandt, 1976) , mouse atrial like HL-1 cells, which pose a atrial cardiomyocyte phenotype (Claycomb et al., 1998) , and primary cardiomyocytes from preclinical animal species, which are not amenable to plate-based high-throughput screening (Hescheler et al., 1991; White et al., 2004) . Recent advancements in stem cell biology, in particular the commercialization and industrial scale differentiation into stem cellderived cardiomyocytes (Abassi et al., 2012) , potentially offer an opportunity for providing a physiologically relevant model system that is amenable to high-throughput screening. The utility of stem cell-derived cardiomyocytes for the prediction of drug-induced ECG abnormalities is well documented (Abassi et al., 2012; Caspi et al., 2009; Guo et al., 2011; Laposa, 2011; Rolletschek et al., 2004; Zeevi-Levin et al., 2012) . Thus, stem cell-derived cardiomyocytes maybe a potential model to investigate structural cardiotoxicity. Live-cell fluorescent imaging of human hepatocyte models has shown the utility of phenotypic profiling in the in vitro detection of drug-induced liver toxicity (O'Brien et al., 2006; Xu et al., 2008) . Here, we have phenotypically profiled a panel of structural cardiotoxins in human embryonic stem cell-derived cardiomyocytes (hESC-CMs) and H9c2 cells and also assessed their effect on contractility in freshly isolated canine cardiomyocytes. We show that this experimental approach is not only capable of predicting the risk of structural cardiotoxicity of novel compounds during early phases of drug development but also provides insight into the mechanisms of structural cardiotoxins.
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Materials
All reagents were purchased from Sigma-Aldrich (St Louis, MO) or synthesized in-house. Cell culture consumables were purchased from VWR (Lutterworth) unless mentioned otherwise and were of the highest purity/grade available. CellTiter-Glo Luminescent Cell Viability Assay Kit was purchased from Promega (Madison, WI). Tetramethylrhodamine ethyl ester perchlorate (TMRE), ER-Tracker blue, TOTO-3, and Fluo-4 AM were purchased from Molecular Probes (Life Technologies, Paisley).
Compound Classification
Compound classification of structural cardiotoxins was gathered using Pharmapendium (https://www.pharmapendium.com). Classical terminologies for cardiac injury (i.e., cardiomyopathy, myocarditis, and heart failure) were used to identify compounds in Pharmapendium with clinical adverse event reports for cardiotoxicity. All classifications were manually checked for the occurrence of structural cardiotoxicity in the Food and Drug Administration (FDA) approval package (Supplementary table 1) . A compound was classified as a nonstructural cardiotoxin if no reports of the above clinical assertions were present in the FDA approval package. Maximum therapeutic plasma concentrations (Cmax) were obtained from Pharmapendium for all clinical compounds with the exception of fluorouracil (Bocci et al., 2000) . In addition, a number of AstraZeneca (AZ) internal drug candidates were classified, based on the occurrence of histopathological abnormalities in 1-month preclinical rat or dog toxicology studies (Supplementary table 2) .
Cell Culture
Human embryonic stem cell-derived cardiomyocytes. hESC-CMs (Cytiva) were purchased from General Electric Healthcare and grown in RPMI 1640 media (Life Technologies 61870044) containing B27 supplement (Life Technologies 17504) in matrigel (BD)-coated 384-well plates according to the manufacturer's protocol.
H9c2 cell line. The H9c2 myoblast cell line, originally derived from embryonic rat hearts (Kimes and Brandt, 1976) , was purchased from the American Type Culture Collection (ATCC, Manassas, VA) and grown in Dulbecco's Modified Eagle's Medium (Sigma D6429) supplemented with 10% fetal bovine serum and kept in 5% CO 2 at approximately 37°C, and the cells were not allowed to grow above 60% confluence. Cells were used up to passage 18. For compound testing, cells were plated at 10,000 cells/well in 96-well plates in 100 µl media and allowed to attach for 24 h, prior to treatment.
Canine cardiomyocytes. Ventricular cardiomyocytes were isolated from beagle dogs as described (Abi-Gerges et al., 2010) , in accordance with the Guide for The UK Home Office Code and Practice for the Housing and Care of Animals used in scientific procedures.
Measurement of Cardiomyocyte Contractility
Cardiomyocyte contractility was measured and analyzed as described in Harmer et al. (2012) using the IonOptix system (Dublin, Ireland); however, cells were exposed to each test compound concentration for ~300 s or until a steady state was achieved.
Compound Preparation
All compounds were dissolved in 100% dimethyl sulfoxide (DMSO) (vol/ vol) as 20mM stock solutions, and insolubility and precipitation were not seen with any compound (assessed by visual inspection) at this 20mM stock. Test compounds were prepared using six concentrations in a fivefold dilution scheme and added to wells of a 96-or 384-well plate to give the indicated final compound concentrations. Final DMSO concentration was 0.5% (vol/vol). Cells were exposed to compound for 6, 24, or 72 h, with a complete re-dose of compound at 48 h. Compounds were screened in triplicate, and the final compound concentration range was 0.03-100μM.
Imaging Parameters
After 72 h of compound treatment, the media was removed, and the hESCCMs or H9c2 cells were stained with fluorescent probes in cell culture media at 37°C for 1 h. The fluorescent probes used were ER-Tracker blue (1nM) to measure endoplasmic reticulum integrity (ER integrity), Fluo-4 AM (1nM) to measure Ca 2+ mobilization, TOTO-3 (1nM) to measure membrane potential (MP), and TMRE (30pM) to measure mitochondrial membrane potential (ΔΨm). Changes 318 POINTON ET AL.
in whole-cell TMRE fluorescence can be due to changes in both plasma and mitochondrial membrane potential; therefore, any changes observed in TMRE only partly reflect a change in ΔΨm (Gerencser et al., 2012) . Following staining, cells were washed with Hank's balanced salt solution (HBSS, Sigma) without calcium and magnesium once and subjected to automated live-cell fluorescent image acquisition using an ImageXpress machine (Molecular Devices, ×20 objective), with an environmental chamber attached (37°C and 5% CO 2 ). Four image fields per well were obtained. Fluorescent images were captured according to the optimal excitation and emission wavelengths of each probe. Identical experiments were subsequently conducted following 6 and 24 h compound exposure.
Image Analysis
Image analysis was performed using metaXpress software (Molecular Devices). A series of measurements of each fluorescent probe were obtained for each drug. They were mean cell integrated intensity for each wavelength measured. The sum of these numerical measurements from the four image fields was combined. Values from the same treatment on three occasions were averaged and then normalized by the average values from the vehicle-treated wells. All vehicle-treated wells in a plate had an average value of 1, and each drug treatment was expressed relative to 1.
Measurement of Cellular ATP Content
Immediately following image acquisition, cellular ATP concentrations were assessed using the CellTiter-Glo Luminescent Cell Viability Assay as per the manufacturer's instructions (Promega); HBSS was removed, and cells were briefly washed once with HBSS and replaced with 100 μl of fresh cell culture media prior to the addition of the CellTiter-Glo reagent. This assay is a luminescence method based on the luciferase/luciferin reaction, which determines the number of viable cells present in a well based on ATP levels. Data from the same treatment on three occasions were averaged to represent the mean ATP measurement.
Data Analysis
Concentration-effect curves were plotted for each compound and expressed relative to vehicle (0.5% DMSO) ± SD. The molar concentration of test compound producing 50% inhibition (IC 50 ) or 50% response (EC 50 ) was calculated using Graphpad Prism (La Jolla, CA) to fit data to a four-parameter nonlinear regression curve. The maximum (DMSO control) values were fixed. Each IC 50 / EC 50 was generated in triplicate for each compound, and geometric means and 95% confidence interval were subsequently calculated. Receiver operator characteristic (ROC) curves were plotted using Graphpad Prism. Therapeutic index (TI) was calculating by dividing the obtained IC 50 or EC 50 by each compound Cmax concentration. F-tests to compare the concentration response curves respectively were performed using Graphpad Prism.
rESUlTS
Multiple Cellular Imaging Parameters and Cell Viability Enable the Detection of Structural Cardiotoxins
To identify the most appropriate assays to investigate structural cardiotoxicity in vitro, hESC-CMs were assessed through live-cell fluorescent imaging of ΔΨm, Ca 2+ mobilization, ER integrity, and MP ( Fig. 1 and Supplementary fig. 1 ). These imaging parameters were combined with an assessment of cellular viability (ATP depletion), following 72 h exposure to clinical and AZ internal drug candidates with a structural cardiotoxicity report. Measuring a number of parameters simultaneously is mechanistically insightful by identifying the parameter modulated at the lowest concentration. For example, in hESCCMs, sunitinib malate preferentially reduced Ca 2+ mobilization prior to modulation of other parameters (ΔΨm, ER integrity, MP, and ATP depletion) (Fig. 1B) . In contrast, at the same concentration (0.16μM), little change was observed in H9c2 cells (Fig. 1D ). These multichannel images were further quantified by automated image analysis algorithms, allowing concentration-effect curves to be generated and IC 50 /EC 50 values to be calculated (Figs. 1E and 1F ).
As the outcome of a drug being either toxic or nontoxic is determined by exposure, it is important to take into account therapeutically relevant maximum plasma concentrations (Cmax) when investigating toxicity. The lowest geometric mean IC 50 / EC 50 (n = 3) obtained in either ATP, ΔΨm, Ca 2+ mobilization, ER integrity, or MP assays was normalized to the Cmax of each compound and expressed as a ratio, TI. We then assessed the relative contribution of ATP depletion and imaging parameters for hESC-CMs (Fig. 2) and H9c2 cells (Supplementary fig. 2 ) by comparing the distribution of each individual compound TI for ATP depletion and the imaging parameter resulting in the lowest IC 50 /EC 50 . Our data show that the structural cardiotoxicity of compounds could be associated with four categories: (1) both ATP assay and imaging parameters were predictive, (2) an imaging parameter was most predictive, (3) ATP depletion was most predictive, and (4) cardiotoxicity was not detected by either ATP assay or an imaging parameter at or below Cmax (Fig. 2) . In general, the imaging parameters gave greater sensitivity than ATP depletion for the detection of structural cardiotoxicity at therapeutically relevant concentrations in both hESC-CMs and H9c2 cells.
hESC-CMs Are a Sensitive In Vitro Model for the Assessment of Structural Cardiotoxicity
To identify which cell model was most predictive of structural cardiotoxicity, 32 clinical and AZ internal drug candidates without a structural cardiotoxicity liability in animal toxicity studies were also included with the positive compounds to calculate the sensitivity and specificity of hESC-CMs and H9c2 cells (Supplementary tables 1 and 2) . The most sensitive TI (ATP depletion, ΔΨm, ER integrity, Ca 2+ mobilization, and MP) for each compound was used to generate the ROC curve (Fig. 3) . A ROC curve is an exhaustive approach to examine paired truepositive (sensitivity) and false-positive rates (specificity) for all possible thresholds for each model (Lasko et al., 2005) allowing the outcome of compound effects in either hESC-CMs or H9c2 cells to be compared with the known effects in vivo. Our data show that hESC-CMs offered improved detection of structural cardiotoxicity, illustrated by the ROC curve for hESC-CMs being closest to the top-left corner. Overall, hESC-CMs detected 25 out of the total 34 structural cardiotoxins at or below Cmax concentrations (Fig. 3) , compared with 18 out of a total of 34 in H9c2 cells. For example, exposure to sunitinib malate resulted in a TI of 0.003 and 32 in hESC-CMs and H9c2 cells, respectively. For only one clinical structural cardiotoxin (clozapine) and two AZ internal drug candidates, the reverse was seen (clozapine TI of 39.9 and 0.06 in hESC-CMs and H9c2 cells, respectively).
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Using ROC curves, appropriate cutoff levels to determine if a compound was detected in a model system can be selected; we found that an IC 50 value of 10μM or below gave optimal sensitivity and specificity. Using this threshold, the assay sensitivity was 74% and 68% in hESC-CMs and H9c2 cells, respectively, and assay specificity was 74% and 50% in hESC-CMs and H9c2 cells, respectively. As hESC-CMs offered greater specificity and sensitivity at therapeutically relevant concentrations, they were used from this point, as the most relevant in vitro model to investigate structural cardiotoxicity.
Relationship Between Structural and Functional Cardiotoxicity
As hESC-CMs offer an improved model to investigate structural cardiotoxicity compared with H9c2 cells and they spontaneously beat, we evaluated the role of the spontaneous beating phenotype in the development of structural cardiotoxicity. hESC-CMs were coadministered with 30μM N-benzyl-p-toluene sulfonamide (BTS, a negative inotrope) to modulate the beating of hESC-CMs with 13 clinical structural cardiotoxins; inactive structural cardiotoxins (isoproterenol HCl and cyclophosphamide) identified in the previous investigation were excluded (Fig. 4) . BTS elicited no toxic response in hESCCMs, as measured by ATP levels (Fig. 4A ). This indicates that any modulation of the cardiotoxicity would be a result of the coadministration and not of BTS in isolation. Overall, in the presence of BTS, 10 out of 13 compounds resulted in shifting concentration-effect curves to the right, to varying degrees, compared with compound alone (Fig. 4B) , with the remaining three compounds shifting concentration-effect curves to the left (Fig. 4C) . A ratio of the IC 50 /EC 50 obtained following each compound with and without BTS was calculated to allow the
FIG. 1. Representative images of hESC-CMs (A and B) and H9c2 cells (C and D)
treated for 72 h with 0.5% DMSO (vehicle) and 0.16μM sunitinib malate. Each set of images was obtained from the same image field, with columns 1-5 being images of all parameters, ΔΨm, Ca 2+ mobilization, ER integrity, and MP, respectively, scale 100 μm. Following image acquisition, a series of measurements from each image were obtained allowing concentration-effect curves to be plotted for hESC-CMs (E) and H9c2 cells (F) (n = 3, mean ± SD). 320 POINTON ET AL. relative comparison of the magnitude of the shift to be compared between compounds (Fig. 4D) . Identical experiments were performed in H9c2 cells, but no modulation of response was observed (data not shown). These data suggest that the presence of the beating phenotype is important for the development of structural cardiotoxicity, highlighting the intricate relationship between cardiac functional and structural cardiotoxicity. In order to provide greater insight into this relationship, we accessed the ability of the clinical structural cardiotoxins to modulate cardiomyocyte contractility. A validated in vitro assay in freshly isolate canine cardiomyocytes that is able to predict the in vivo contractility outcome (Harmer et al., 2012) was applied. Overall, quantifiable IC 50 /EC 50 values were obtained for 8 out of 15 structural cardiotoxins tested (Fig. 5) . All eight compounds were found to be negative inotropes, with the exception of isoproterenol HCl, which was a positive inotrope. However, when the TI was calculated, we found that 11 out of 15 compounds either inactive or modulated contractility at concentrations greater than Cmax (TI > 1). The remaining four compounds (amiodarone, amphotericin B, cyclophosphamide, and isoproterenol) affected contractility at or below Cmax values highlighting an acute functional consequence.
Classification of Compounds Into Thematic Mechanisms Reveals Mitochondria and Ca 2+ Mobilization to Be the Major Distal Targets
By taking into consideration the therapeutic concentration of each compound and comparing this to the IC 50 /EC 50 value generated in each assay (ATP, ΔΨm, Ca 2+ mobilization, ER integrity, MP or canine contractility), compounds were classified into thematic mechanistic categories based on each individual compound response at the lowest therapeutically relevant IC 50 / EC 50 . This allows the primary response for a compound to be separated from subsequent secondary responses. In order to apply this to our data, responses occurring at concentrations 0.1, 0.5, 1, and 5 times Cmax concentrations were separated allowing a pathway of assay changes for each compound to be constructed. This analysis revealed compounds fell into multiple different thematic categories (Fig. 6) , highlighting structural cardiotoxicity to be multifactorial and complex in nature. Despite this broad array of mechanisms of action, changes in either ΔΨm or Ca 2+ mobilization in isolation or combination with other parameters were found to be characteristic of 11 of the 15 structural cardiotoxins evaluated. This indicates that mitochondria and Ca 2+ mobilization should be considered as a major distal target for structural cardiotoxins.
In order to gain greater insight into the upstream initiating mechanisms, parameters were re-run following 6 and 24 h exposure to each compound (Supplementary fig. 3 ). We found that early time points (6 and 24 h) did not allow insight into the mechanisms of toxicity due to the lack of detection of structural cardiotoxins at these time points.
FIG. 2.
Distribution maps between cell viability (ATP depletion) and imaging parameters in hESC-CMs. The geometric mean IC 50 /EC 50 (n = 3) obtained in either ATP depletion or an imaging parameter (ΔΨm, Ca 2+ mobilization, ER integrity, or MP) were normalized to Cmax and expressed as a ratio (TI). A value of 1 or below indicates the IC 50 /EC 50 for an assay was either at or below Cmax concentrations, whereas a value greater than 1 indicates the IC 50 /EC 50 for an assay was above Cmax concentrations. Clinical structural cardiotoxins are highlighted according to compound numbers listed in Supplementary table 1; points without numbers are the AZ internal drug candidates. The plot shows the number of compounds detected by both, ATP depletion and an imaging parameter, quadrant 1, ATP depletion alone, quadrant 3, an imaging parameter alone, quadrant 2, or compounds not detected at or below Cmax concentrations, quadrant 4. When an imaging parameter was affected below Cmax concentration, the identity of the imaging parameter resulting in the lowest TI is highlighted in color, with the black points representing AZ internal drug candidates or clinical structural cardiotoxins.
FIG. 3. Determination of the predictivity of H9c2 cells (open circles)
and hESC-CMs (closed circles) to detect structural cardiotoxins. The lowest geometric mean IC 50 /EC 50 (n = 3) obtained in either ATP, ΔΨm, Ca 2+ mobilization, ER integrity, or MP assays was normalized to the Cmax of each compound, expressed as a ratio (TI), and subjected to ROC analysis. The dotted line shows the results of random assignment of cardiotoxicity.
STRUCTURAL CARDIOTOXICITy In VITRo
dISCUSSIOn
Detection of structural cardiotoxicity early during the drug discovery process by in vitro methods is a current unmet need. Using live-cell fluorescent imaging in conjunction with a measure of cellular viability (ATP depletion), we report that hESCCMs provide a high-throughput experimental model to detect structural cardiotoxicity liabilities in novel compounds at therapeutically relevant concentrations. Moreover, our data provide insight into the intricate relationship between functional and structural cardiotoxicity and demonstrate the diversity of the mechanisms of action of structural cardiotoxins.
Although some kinase inhibitors were found to result in structural cardiotoxicity in neonatal rat cardiomyocytes and H9c2 cells (Hasinoff, 2010; Will et al., 2008) , an in-depth analysis of different structural cardiotoxin drug classes and direct comparison of different in vitro models has not been reported. For this reason, we evaluated the effects of 72 h exposure to 34 clinical and AZ internal drug candidates with known in vivo structural cardiotoxic liabilities and 32 clinical and AZ internal drug candidate nonstructural cardiotoxins on ΔΨm, Ca 2+ mobilization, ER integrity, MP, and ATP depletion in hESC-CMs and H9c2 cells. Our data suggest that hESC-CMs in combination with imaging parameters and assessment of ATP content were able to predict the in vivo outcome with an overall sensitivity and specificity of 74%, providing an appropriate model for the assessment of structural cardiotoxicity. This compares well to a recent published framework to assess the translation of in vitro data to findings in in vivo models and humans (Genschow et al., 2002; Spielmann et al., 2006; Valentin et al., 2009) .   FIG. 4 . Impact of beating rate on structural cardiotoxins. ATP content was measured following 72 h exposure to BTS (n = 3, mean ± SD) in hESC-CMs (A). Clinical structural cardiotoxins were coadministered with 30µM BTS for 72 h and subjected to measurement of the lowest parameter (ATP depletion, ΔΨm, ER integrity, Ca 2+ mobilization, or MP) used to plot the ROC curve. Concentration-effect curves were plotted to allow visualization of shifts in potency to the right (B) and left (C) (n = 3, mean ± SD). IC 50 /EC 50 values from each compound condition were calculated and data expressed as a ratio of the IC 50 /EC 50 following BTS coadministration to the IC 50 /EC 50 following compound alone (D). A ratio value ≥ 1 indicates that BTS was found to be protective against compound cardiotoxicity, whereas a value ≤ 1 indicates an enhancement of the compound cardiotoxicity. Overall, the majority of compounds displayed varying degrees of cardioprotection when coadministered with BTS.
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Little is currently known about the relationship between functional and structural cardiotoxicity. Our data, for the first time, demonstrate the importance of the beating phenotype of hESC-CMs. Preliminary experiments with verapamil (negative inotrope that has its effect mediated via inhibition of the L-type calcium channel) (data not shown) resulted in comparable results to BTS. As both BTS and verapamil reduce beating rate, this finding highlights the importance of a controlled beating rate for structural cardiotoxicity to manifest and provides an experimental approach to identify structural cardiotoxins from other compounds that are cytotoxic across a range of cell types. Because coadministration of these negative inotropes resulted in a decrease in sensitivity, it is plausible to postulate that under control conditions the spontaneous beating phenotype of hESCCMs allows an improved sensitivity to structural cardiotoxins; however, the mechanism by which this cardioprotection results remains unknown. However, it could be speculated that beating and nonbeating cells have differential energy requirements, perhaps allowing smaller modifications in the cellular ATP pool to have a greater impact on cellular health in beating cells.
We also found that only four clinical structural cardiotoxins (amiodarone, amphotericin B, cyclophosphamide, and isoproterenol) assessed in this study modulated canine cardiomyocyte contractility at concentrations below Cmax, indicating that acute functional effects were not relevant for the majority of these cardiotoxins. However, this finding does not preclude the occurrence of functional cardiotoxicity with chronic exposure, or as a secondary consequence upon marked morphological damage to cardiomyocytes. Conversely, the four structural cardiotoxins that affect contractility are likely to be primarily functional cardiotoxins, resulting in secondary structural cardiotoxicity liabilities. Further investigation of other aspects of functional cardiotoxicity is required before we can conclusively define them as functional cardiotoxins. Overall, the relationship between functional and structural cardiotoxicity appears to be dynamic, multifactorial, and interlinked. In order to assess all accepts of cardiotoxicity during drug development, all compounds should be assessed for their potential risk to induce both functional and structural cardiotoxicity and form an integrated cardiotoxicity risk assessment. Currently, multiple aspects of functional cardiotoxicity are being assessed , but those associated with structural cardiotoxicity are reliant on histopathology and 
FIG. 6.
Classification of compounds into thematic mechanisms. Compounds were classified into categories based on the pattern of response in each assay in relation to the Cmax concentration. This allowed compound effects to be separated into those occurring at 0.1, 0.5, 1, and 5 times Cmax concentrations, allowing primary and secondary mechanisms to be identified.
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clinical pathology abnormalities during preclinical studies of up to 1 month in duration. Therefore, an in vitro predictive approach, like the one presented in this investigation, could be used during Lead Identification and Lead Optimization phases to mitigate potential structural cardiotoxicity hazards and help reduce the cardiotoxicity risk of novel compounds.
Not all parameters measured, with the exception of MP and in some instances ATP, resulted in gross cell death and their translation to humans remains to be determined. Due to their role in cell death and loss of cardiomyocytes, it could be postulated that both ATP depletion and changes in ΔΨm and membrane potential may lead to the release of biomarkers (e.g., cardiac troponin I or B-type natriuretic peptide) into plasma (Kepp et al., 2011) . In contrast, this may not be the case for changes seen in Ca 2+ mobilization and ER integrity. Within cardiomyocytes, intracellular Ca 2+ concentrations are regulated by Ca 2+ channels, exchange proteins, and ER and mitochondrial membrane systems (Altschafl et al., 2011; Arai et al., 1998; Bers, 2002; Conway and Koushik, 2001; Thomas and Will, 2012) . Modulation of Ca 2+ concentrations can result in apoptosis, mitochondrial damage, and arrhythmias (Gwathmey et al., 2009; Qian and Guo, 2010) . During cellular deregulation, Ca 2+ removal is restricted to the plasma membrane, with the sodiumcalcium exchanger (NCX) acting in forward mode (Dipla et al., 1999; Mattiello et al., 1998) . Under this condition, if NCX is unable to remove intracellular Ca
2+
, functional abnormalities and cell death may occur. Clinically, contractility abnormalities will present as changes in LVEF, suggesting the occurrence of functional cardiotoxicity. However, it is unclear how changes in LVEF correlate with changes in cardiac biomarkers. Recent studies have found a good correlation between LVEF and measurement of B-type natriuretic peptide (Rostagno et al., 2011) . Thus, more insight into the clinical manifestation of structural cardiotoxicity is needed before greater distinction of structural and functional cardiotoxicity parameters in vitro can be achieved.
Even though we have not exhaustively examined all drugs that have been marketed to date and nor have we measured all cellular and biochemical parameters, a combination of a number of cellular fluorescence imaging parameters and ATP depletion may help to gain insight into mechanisms of structural cardiotoxins. Nevertheless, alterations in one parameter may not be independent or mutually exclusive in the biological sense. For example, changes seen in ΔΨm at lower concentrations may prelude to apoptotic cell death and ATP depletion or loss of ER integrity through changes in ATP synthesis. On the other hand, ΔΨm changes seen at higher concentrations may drive the accumulation of Ca 2+ into the mitochondria from the ER (Bers, 2002; Duchen, 2004; Lu et al., 2010) . Altogether, these changes may allow important mechanistic insight into mechanisms of toxicity. Our classification of compounds into thematic mechanisms revealed a diverse array of mechanisms, with compounds from the same chemical class displaying a variety of profiles, indicating that structural cardiotoxicity is not a compound class effect. Although, 11 of the 15 structural cardiotoxins that were evaluated changed ΔΨm or Ca 2+ mobilization, suggesting these processes are major distal targets for structural cardiotoxins, although the upstream initiating mechanisms remain to be identified. Given the central role of mitochondria in apoptosis (Dykens and Will, 2007; HeathEngel and Shore, 2006; Regula and Kirshenbaum, 2005) , cardiac injury may be an inevitable consequence of the gradual mitochondrial dysfunction observed in this work and in other studies (Lax et al., 2009 ). Therefore, caution should be applied when interpreting any observed mitochondrial effects resulting from drug treatment as representing direct drug-induced mitochondrial toxicity. Nonetheless, such information may allow insight into modes of cell death if coupled with other parameters.
In conclusion, our data show that hESC-CMs provide a suitable model for the investigation of structural cardiotoxicity during drug development. If used in this way, an improved balance between efficacy and safety of novel compounds might be reached.
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